Cargando…

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult

Detalles Bibliográficos
Autores principales:	Boeck, S, Haas, M, Ormanns, S, Kruger, S, Siveke, J T, Heinemann, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200105/ https://www.ncbi.nlm.nih.gov/pubmed/24642615 http://dx.doi.org/10.1038/bjc.2014.60

Ejemplares similares

The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy
por: Ormanns, Steffen, et al.
Publicado: (2017)

Reply to: The definition of locally advanced pancreatic cancer
por: Boeck, S, et al.
Publicado: (2010)

Open conversion for laparoscopically difficult cholecystectomy is still a valid solution with unsolved aspects
por: Mannino, M., et al.
Publicado: (2019)

Prediction of neoadjuvant chemotherapy response in breast cancer
por: Myllys, Maiju
Publicado: (2021)

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer
por: Haas, Michael, et al.
Publicado: (2017)

Innovative management of difficult paediatric airway, using antegrade seldinger technique
por: Jain, Anuj, et al.
Publicado: (2019)

Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma
por: Liu, Zhi-Peng, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
por: Guenther, Michael, et al.
Publicado: (2023)

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Difficult tracheostomy in a case of difficult mask ventilation and difficult intubation?
por: Kumar, Mritunjay, et al.
Publicado: (2013)

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research
por: Baechmann, Sibylle, et al.
Publicado: (2017)

Still a hopeless case for personalized oncology? Pancreatic cancer revisited
por: Weichert, Wilko, et al.
Publicado: (2018)

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Sams, L., et al.
Publicado: (2021)

A case of fiberoptic bronchoscopy used as innovative aid for life saving in difficult surgical tracheostomy patient
por: Mishra, Nitasha, et al.
Publicado: (2019)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
por: Gogia, Ajay, et al.
Publicado: (2018)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Kuerer, Henry M, et al.
Publicado: (2016)

Regarding “Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs”
por: Su, I-Hsuan, et al.
Publicado: (2023)

Management of a difficult-to-ventilate and difficult-to-intubate airway: Anesthetists’ nightmare
por: Naik, B. Naveen, et al.
Publicado: (2018)

Difficult airway with paediatric Tetralogy of Fallot: Cohesion of two difficult situations
por: Garg, Heena, et al.
Publicado: (2021)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

Unanticipated difficult airway
por: Panwar, Vishnu, et al.
Publicado: (2013)

An Evolving Difficult Airway
por: Mohan, N. Midhun, et al.
Publicado: (2017)

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023)

Reply to Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Heil, Joerg
Publicado: (2016)

Benefits of screening cancer patients for distress still not demonstrated
por: Coyne, J C
Publicado: (2013)

Neoadjuvant chemotherapy alters peripheral and tumour‐infiltrating immune cells in breast cancer revealed by single‐cell RNA sequencing
por: Zhou, Hanlin, et al.
Publicado: (2021)

Difficult Cases
por: Wilson, J.
Publicado: (1888)

Long-lasting response to third-line chemotherapy in metastatic pancreatic cancer
por: Tavares, Alda, et al.
Publicado: (2020)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
por: Ormanns, Steffen, et al.
Publicado: (2014)

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
por: Kruger, S.F., et al.
Publicado: (2022)

Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma
por: Shoucair, Sami, et al.
Publicado: (2022)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

Clostridium difficile phages: still difficult?
por: Hargreaves, Katherine R., et al.
Publicado: (2014)

Prediction is very difficult, especially about the future
por: Tomšič, Anton, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3m655vnsnptit1tcd9i9n26rvj